**Diabetes**

Chronic metabolic disorder characterized by elevated blood glucose levels due to deficiency in insulin production or insulin resistance.

Type 1 and type 2 diabetes
These terms describe aetiology of the condition but the preferred terms are IDDM and NIDDM which classify the condition in terms of treatment needed
Type 1 diabetes
acute beta cell failure leading to insulin deficiencyWhen 90% of the beta cells have been destroyed, the patient presents with:
polydipsia
polyuria
weight loss
glycosuria
ketonuria
often a faint smell of acetone on the patient’s breath
Type 2 diabetes
chronic beta-cell failure with insulin resistance
There may be no symptoms or fatigue, visual disturbance, recurrent skin infections

 

Complications
Acute Complications
First or later presentations of T1DM may be a medical emergency with dehydration, ketoacidosis, and hyperglycaemic coma.
HONK etc
Macrovascular disease accelerated atheroma
Coronary arteries, with a greatly increased risk of early coronary heart disease (CHD), IHD and MI
Cerebral arteries, with an increased risk of CVA
all of the other large arteries, with an increased risk of blockage by thrombosis
Microvascular disease affecting the small peripheral arteries
hypertension
diabetic retinopathy and blindness
peripheral ischaemia – skin, nerves and other tissues of the lower limbs(some diabetic neuropathies are due to nerve ischaemia caused by small artery blockage; other diabetic neuropathy is due to lesions of the sensory and motor nerves themselves)
source MacGavock

 

Glucose / insulin physiology

youtu.be/cTDWZp4sLuU

youtu.be/nDi02jxXUu4

youtu.be/y3l-rfxY_Ew

youtu.be/p42aOzo8fTw

 

Diabetes Diagnosis
Random or 2hr glucose > 11.1
Fasting >7.0 mmol/l
HbA1c > 6.5% 48mmol/mol
On one occassion with symptoms
(polyuria, polydipsia, unexplained weight loss)or on two separate occasions without symptoms
Diagnosis, classification, and treatment of DM BMJ Sep 2011
HbA1c in the diagnosis of T2 DM – Diabetes UK

 

NIDDM Diabetes Diagnosis using HbA1c
>6.5%
48mmol/mol
with symptoms = DM
>6.5%
48mmol/mol
without symptoms
but confirmed on repeat = DM
<6.5%
48mmol/mol
on repeat
= non-diabetic hyperglycaemia
(prediabetes)
6.0-6.4%
42-48 mmol/mol
OGTT
2hr gluc 7.8-11 mmol/l  = IGT
2hr gluc > 11 mmol/l = DM
<6% /42mmol non diabetic

HbA1c testing is not recommended for diagnosis of type 1 diabetes, and should not be used to diagnose type 2 diabetes in children, or patients with end-stage kidney disease, haemoglobinopathies or anaemia.
A value less than 6.5% does not exclude diabetes diagnosed using glucose tests.

 

HbA1c
HbA1c (%) IFCC (mmol/mol)
6.0 42
6.5 48
7.0 53
7.5 59
8.0 64
9.0 75

hacking-medschool.com/hba1c

Diabetes UK HbA1c

 

Impaired glucose tolerance and raised fasting glucose
Impaired Glucose Tolerance
fasting glucose < 7
2hr OGTT >7.8 but less than 11.1
Read code R10D
Impaired Fasting Glucose
fasting glucose between 6.1-7 and OGTT <7.8 @ 2hrs
Read code R10E
Reduction in insulin secretion and the development of insulin resistance with increasing hyperglycaemia probably occur gradually over several years before type 2 diabetes is diagnosed. Patients are with IGT/IFG are already already carrying the risks of diabetes, which can be reduced before waiting for diabetes proper to develop
Glucose Tolerance Tests Patient UK

 

Preventing Type 2 diabetes

Preventing Type 2 diabetes NICE PH35

 

Diabetes Screening
may be worthwhile in patients in higher risk population – over 40 with one/two or more of the belowrecent UK guidance calls for much wider annual screening in “high risk” individuals
1st degree relatives with diabetes or heart disease
BMI > 30 (>27.5 South Asian or Chinese)
Organ damage known to be associated with diabetes – retinopathy, CKD, neuropathy
CVD, hypertension or dyslipidaemia
Conditons asoc with diabetes – PDOS severe mental health disorder
current meds assoc with increased risk of diabetes eg corticosteroids newer antipsychotics

 

Diabetes – initial assesment and management
Exclude secondary causes such as pancreatic disease, hormone-induced diabetes, steroids or thiazides neuroleptics
Check smoking, diet, and exercise habits.
Measure BP, weight, height BMI
Examine for any existing complications
Initial investigations: HBA1c, FBC, RFTs, fasting lipids, and microalbuminuria
Give initial dietary advice
healthy balanced diet, with restriction of refined sugars.Most patients should have a three month trial of dietary treatment before starting on oral hypoglycaemic agents.
provide written information and instructions.Initial education may involve just a simple explanation of the nature of diabetes and clear advice on action to be taken if the condition deteriorates
Organizational tasks – Read coding , Diabetes Registers CVS Risk profiling
Referral for assessment of eye complications; and referral to dietician, chiropodist or podiatrist, and community diabetes educator, if available
immediate referral if patient unwell, has ketonuria, or blood glucose > 20 mmol/l.
Recent weight loss is an indication of severity of disease

 

Initial dietary advice for the newly diagnosed diabetic

1. Avoid sugary drinks i.e. pop and squash
2. Do not add sugar to foods or drinks e.g.cereals, tea, coffee, etc.
3. Reduce your intake of sugary foods by avoiding Jams, marmalade, honey, syrup, cakes, sweet biscuits and pastries, sweets, chocolate, puddings, sugar coated breakfast cereals.
5. Eat regular meals Try to have something to eat at breakfast, lunch, tea and supper
6. Eat plenty fruit and vegetables
7. Do not buy diabetic foods These foods are not necessary and are best avoided.

high in soluble fibre,
low in saturated fats, contain plenty of poultry, fish and veal
carbohydrate from whole grain products (for slow release of glucose)
and supply no more than the estimated daily calorie requirement.
– avoid low cal drinks
– dont obtain calories from drinks
Diabetes prevention lifestyle targets: weight reduction >5% if obese, fat intake <30% of energy intake, saturated fat
<10% of energy intake, fibre >15g per 1000 calories, exercise 4 hours/week. Normal dietary NaCl.

Smoking cessation, physical activity, weight control (5-10% loss per year if overweight).
Structured education: especially self-management, beliefs, knowledge, skills involve carers.
Regular follow-up with complete annual review.

Glycaemic index diabetes uk

dsolve diabetes

 

Starting insulin
Initial 0.6 x body weight (kg) in divided doses
basal 50-66%
rest divided between meals
0.5 multiplier athlete
0.6 exercisers – first phase of menstrual cycle
0.7 late menstrual cycle
1st trimester
pregnancy viral illness
newly diagnosed child
0.8 second trimester
severe viral infection
puberty
0.9 third trimester
bacterial infection
1.0 pregnancy – term
severe bacterial infection
late puberty
1.5-2 ill adolescent
peak of punescence
Honeymoon period final surge in endogenous insulin secretion when starting insulin
requirements may drop
eg 0.2-0.6 u/kg/day
DM pocketflyer Borm
diabetes.nhs.uk safe use of insulin
NHS Diabetes insulin
NPSA Insulin Passport

 

Insulin preparations
Human rapid acting Actrapid
intermediate NPH insulatard
mixtures varying proportions of short and intermediate acting
eg humulin M1
(10% short:90% intermediate)
humulin M3
(30%:70%)
Analogue ultra short lispro
aspart
glulisine
long acting glargine
detemir
mixtures ultrashort analogue + intermediate
Animal (bovine and pork) now rarely used

MIMS Table Insulin Preparations

Insulin Analogues NPC Rapid Review Oct 2011

 

Insulin regimes
bd insulin
Short acting insulin mixed with intermediate acting insulin bd before meals
eg Novomix 30 Humulin M3 Humalog mix 25
Biphasic insulin aspart 30/70 bd
tds insulin
Short acting insulin mixed with intermediate acting insulin before breakfast
plus short acting insulin: before evening meal
plus intermediate acting insulin: at bedtime.
basal bolus regime
intermediate / long acting acting insulin at bedtime (basal)
plus short acting insulin tds (breakfast, lunch and evening meal) (bolus)
eg insulin aspart and insulin glargine or insulin etemir
once daily regime
may suffice for some patients with T2DM needing insulin
Intermediate acting insulin with or without short acting insulin
either before breakfast or at bedtime
otherwise use above regimes

Insulin is injected subcutaneously varying the site of injection from the abdomen to the thighs, upper arms and buttocks.

 

Starting insulin in type 2 diabetics

Initiating Insulin in Type 2 diabetes NHS CKS

Starting insulin in type 2 diabetes diabeticretinopathy.org.uk

Which insulin, regimen and device in type 2 diabetes? DTB 2010;48:134

 

Diabetes illness rules
Infections stimulates release of insulin antagonists, causing a rise in daily insulin requirements.If the patient becomes ill they should measure BMs several times per day and to test the urine for ketones
(some BM metersdo this now)Insulin dependent diabetics should be admitted to hospital if:
there are ketones in the urine
there is persistent vomiting
there is abdominal pain
compliance is known to be poor
the patient is a child.Patients with T1DM who develop concomitant illness should:
continue with insulin
measure blood glucose at least four times a day
test for ketones once a day
aim to drink just under 3l unsweetened fluids per day
adjust the dose of insulin according to the measurement of blood glucose and presence, or not, of urinary ketones
Less than 13mmol/l ketones Increase the dose of each insulin injection by 2 u continue until ketone clear
Between 13 and 22mmol/L no ketones Increase the dose of each insulin injection by 2 u continue until blood glucose controlled
Between 13 and 22mmol/l ketones Increase the dose of each insulin injection by 4 u continue until ketones clear
Greater than 22mmol/l no ketones Increase the dose of each insulin injection by 4 u continue until blood glucose controlled
Greater than 22mmol/l ketones Increase the dose of each insulin injection by 6 u continue until ketones clear

Adults with type 2 diabetes who develop concomitant illness should continue taking their normal dose of oral hypoglycaemic agent or insulin as prescribed by the diabetes team and keep testing their urine and blood glucose.

Patients with ketones who develop a low blood glucose (less than 8mmol/L) should supplement their diet with milk or fruit juice to raise their blood glucose.

 

Blood glucose meters and strips

MIMS BM Strips and Meters
Accu-Check Mobile Strip Free Meter

Ketone Meters BJGP Aug 2011
novabiomedical nova_max_plus

abbott optium-xceed

GlucoMen PLUS

 

Finger prickers and lancets

MIMS Table BM Testing – Finger Prickers and Compatible Lancets

 

Diabetes self-monitoring

No good evidence for self-monitoring in non-insulin diabetes Pulse 16/02/2012

HbAlc testing measure routinely at six monthly intervals in all people with diabetes.
Regular self monitoring of plasma glucose levels is essential in type 1 diabetes – SBGM four or more times a day is recommended to prevent hypoglycaemia and control hyperglycaemia.
More frequent SBGM may be indicated in MI,dialysis, pregnancy, terminal care and impaired awareness of hypoglycaemia.
For type 2 diabetics who are not taking insulin SBGM is not usually necessary.
SBGM may be needed if diabetes is destabilised e.g. concurrent severe illness, steroid therapy, pending treatment escalation etc.

If SBGM deployed should be taught by a health care professional using the following guidelines
Routine—Twice weekly random testing (to maintain testing competency)
and
Twice daily for two weeks prior to clinic review
I day —pre breakfast and ihr after breakfast nd
2 day— pre lunch and 1 hr after lunch rd
3 day— pre evening meal and I hr after evening meal th
4 day— pre supper if taken, and pre bed Then repeat as four days cycle until review

BMJ 2007;335:132–6
BMJ 2008;336:1174–7

youtu.be/RG3ioEmoLUo
youtu.be/iTxbv-Mpqfg
youtu.be/SSYJ-ts9X7M
youtu.be/s8nzOrbeM5Q
youtu.be/W245aoH_b4U
youtu.be/MmQzk3f1fKQ

Improving outcomes in type 2 diabetes MeReC Jun 2011

 

Type 2 diabetes treatment steps
Step1 Diet weight loss and exercise
If mild or no symptoms try dietary control over 3 months
Step2 Oral monotherapy
If symptoms or failure to achieve control
metformin first line choice
Step3 Oral combination therapy
If side effects/intolerance/poor control
Step4 Insulin + oral agent
If they still have failed to achieve glycaemic control

Type 2 diabetes drugs  Antidiabetics

 

T2 DM steps

 

Biguanides Metformin
Metformin first choice in type 2 diabetesreduces hepatic glycogenolysis, intestinal absorption and (mildly) insulin resistance.It is cheap, has few side effects, less tendency to hypoglycaemia, helps wt loss/avoiding wt gain, and can be used in heart failureMetformin is renally excreted and accumulation may precipitate lactic acidosis.Patients with deteriorating renal function should be monitored closely.
Review dose if creatinine >130micromol/l or egfr<45ml/min/1.73m2
Stop if creatinine>150 or egfr<30Metformin tablets 500mg, 850mgStart low go slow – increase dose over several weeks to minimise GI side effectsDose: initially 500mg with breakfast for at least 1 week then 500mg with breakfast and evening meal for at least 1 week then 1g with breakfast and 500mg with evening meal for 1 week, then 1g with breakfast and evening meal; max. 3g daily in divided doses (1g with breakfast, lunch and evening meal).Note – The maximum dose of metformin differs between the manufacturer’s Summary of Product Characteristics (3g daily as 3 divided doses) and the BNF (usual max. 2g daily in divided doses). Some patients tolerate up to 3g metformin daily in divided doses and may have additional glycaemic improvement.Metformin prolonged release tablets (Glucophage® SR) is restricted to use in patients who are intolerant of immediate release metformin (due to severe GI side-effects) and in whom the prolonged release tablet allows the use of a dose not previously tolerated.
If no benefit in GI side-effects is seen within 6 months, metformin prolonged release should be stopped and an alternative agent commencedMetformin or glibenclamide are both occ considered as initial pharmacological glucose lowering treatment in women with gestational diabetes depending on fasting and postprandial targets [both unlicensed use].
If however, blood glucose levels are in the range for established diabetes, intensive specialist management and initial therapy with insulin is required.
Sulphonylureas other than glibenclamide should not be used during pregnancy due to placental passage.
youtu.be/cU1tnTWZg7o
youtu.be/mjfzz7bcJwU
youtu.be/pD7YdUdEHdw
youtu.be/q4IK09bwm6E

 

Sulphonylureas
Insulin secretagogues – increase beta cell insulin secretionwarn about risk of hypoglycaemia especialy if renal impairementuse if weight gain not a problem for rapid blood glucose reduction or metformin intolerant/CIGliclazide tablets 80mg
Initially, 40-80mg daily adjusted according to response; up to 160mg as a single dose, with breakfast;
higher doses divided; max 320mg daily.
Gliclazide is principally metabolised in the liver and is preferred in renal failure.Glipizide tablets 2.5mg, 5mg
Initially, 2.5-5mg daily shortly before breakfast or lunch, adjusted according to response; max. 20mg daily; up to 15mg may be given as a single dose; higher doses divided.Glibenclamide
long-acting sulphonylurea with a greater risk of hypoglycaemia
only used in special circumstances eg some women with mild gestational diabetes
youtu.be/B3GpNRIYNekyoutu.be/oWynJVIaE_Ayoutu.be/BtdkbaPS-XY

 

BMJ 2012;344:e1369

both gliptins and incretins  better for wt loss than sulphonylureas and pioglitazone

gliptins lower risk of hypoglycaemia than sulphonylureas

 

 

DDP4 inhibitors aka gliptins – sitagliptin vildagliptin linagliptin
Gliptins
Prandial glucose regulators
These are amino acid derivatives licensed for 2nd or 3rd line use with metformin in type 2 diabetes, where better control is needed, or where patients experience hypoglycaemia when treated with sulphonylureas.The drugs are glucose responsive: so induce insulin release when the patient eats, by acting on the pancreatic betacells to stimulate a rapid, shortlasting release of insulin to a level dependent on the glucose concentration, ie. where there is a postprandial rise in glucose.This is thought to be beneficial where the patient has an erratic lifestyle (e.g. junior doctors)prefer over TZDs if
thiazolidinediones contraindicated
previously poor response or intolerance
or further wt gain would cause significant problems
continue only if HbA1c reduction > 0.5% in 6mSitagliptin
100mg od
monotherapy in patients for whom both metformin and sulphonylureas are inappropriate due to CI or intolerance
in combination with metformin when the addition of a sulphonylurea inappropriate;
or in combination with a sulphonylurea when metformin is not appropriate;
or in combination with both a sulphonylurea and metformin when dual therapy does not provide adequate control.Sitagliptin and metformin combined tablets (sitagliptin 50mg / metformin 1000mg Janumet®?) are available which may offer some patients a more convenient dosing regimen. Their use is restricted to patients for whom this combination is an appropriate choice of therapy either and only when the addition of sulphonylureas to metformin monotherapy is not appropriate or in combination with a sulphonylurea (triple combination therapy) in patients inadequately controlled on their maximal tolerated dose of metformin and sulphonylurea.Saxagliptin may be used as add-on combination therapy with metformin when metformin alone with diet and exercise does not provide adequate glycaemic control.
Use is restricted to patients where the addition of a sulphonylurea is not appropriate.Linagliptin 5mg od

x

 

Meglitinides naglitinide and repaglinide
Second generation insulin secretagoguesless prone to cause wt gain and hypoglycaemia  but expensive an less effective than the sulphonylureas

 

Acarbose (glucobay)

alphaglucosidase blocker
delays intestinal CHO absorption
only consider if unable to use other oral glucose-lowering drugs
youtu.be/NqVXPZs66k8youtu.be/UQDYcMTRTBU

 

Glitazones aka Thiazolidinediones
Pioglitazone
Rosiglitazone
Enhance the effects of insulin in adipose tissue and skeletal muscle (ie reducing insulin resistance).Second line or third line treatment options for management of glycaemic control in patients with type 2 diabetes.prefer over DDP4s if:
marked insulin insensitivity
previously poor response or intolerance
consider combining with insulin when
previous good glucose reduction with TZDs
Pt inadequately controlled on high dose insulinAvoid in HF or osteoporosis risk
continue only if HbA1c reduction > 0.5% in 6mmay be added to metformin and sulphonylurea therapy, or substituted for either in cases of intolerance.May also be used as monotherapy for patients in whom metformin and sulphonylureas are contraindicated or not tolerated.An increased incidence of cardiac failure has been seen with rosiglitazone when used with insulin.It has also been linked to an increase in fracture risk.
The risk of fracture should be considered in the long term care of female patients treated with a thiazolidinedioneCheck LFTs prior to starting treatment and then at two monthly intervals for the first year.
stop if LFTs rise three times the normal level or if the patient becomes jaundiced.Pioglitazone may be combined with insulin under close specialist supervision (risk of heart failure) in patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.Pioglitazone tablets 15mg, 30mg, 45mg
initially, 15-30mg od increased to 45mg od according to response.Pioglitazone is available as a combination product with metformin (pioglitazone 15mg / metformin 850mg Competact®?) which may offer some patients a more convenient, though less flexible, dosing regimen than the separate individual constituents. Use is restricted to patients who cannot be treated with a sulphonylurea in combination with metformin.
It may take up to 8 weeks to achieve maximum effect with the thiazolidinediones (glitazones).The glitazones cause fluid retention and double the risk of heart failure. They are contraindicated in any heart failure (NYHA I-IV). They can rarely cause liver dysfunction; monitor liver function before treatment and periodically thereafter based on clinical judgement. Following new evidence showing increased cardiovascular risk with rosiglitazone compared to pioglitazone highlighted in a recent MHRA safety alert (26th July 2010), rosiglitazone is not recommended for use within NHS Tayside. Further information can be found on the MHRA websiteCases of heart failure have been reported when pioglitazone has been used in combination with insulin, especially in patients with risk factors for the development of heart failure. If the combination is used, all patients should be monitored for signs and symptoms of heart failure, weight gain and oedema, and pioglitazone should be discontinued if any deterioration in cardiac status occurs.
youtu.be/MuaXLyZifrw
youtu.be/ROu3TtSNswY

 

x

GLP agonists – Exenatide Liraglutide NICE Exenetide
Bind to and activate the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppress glucagon secretion, and slow gastric emptying.Third line therapies initiated in secondary care.
Given by subcut injection.
In Tayside liraglutide is preferred over exenatide (in patients with eGFR>60mL/min) due to greater efficacy, lower rates of nausea, and a once daily administration.Liraglutide
may be considered in type 2 diabetic patients with eGFR >60mL/min in combination with metformin and/or a sulphonylurea or metformin and a thiazolidinedione in patients with insufficient glycaemic control despite maximal tolerated doses of monotherapy with metformin or sulphonylurea or despite dual therapy with metformin and a sulphonylurea or metformin and a thiazolidinedione.Exenatiderestricted to type 2 diabetic patients with eGFR 30-60mL/min in combination with metformin and/or sulphonylureas or metformin and a thiazolidinedione in patients who have failed to achieve glycaemic control on maximally tolerated doses of these oral therapies
or in patients for whom glitazones are unsuitable (e.g. due to heart failure, hepatic impairment or where rapid glycaemic control is required) and who would otherwise move to insulin therapy.Exenatide: Consider if BMI >35 kg/m2 or weight-gain specific important issue, HbAlc >7.5% (>58 mmollmol), instead of insulin or TZD.Only continue if >1% reduction of HbA1c and >3% wt loss at 6m
NHS Tayside Guidelines for oral antidiabetic drugs

 

T2 DM Drugs Names
Biguanides Metformin  Glugophage
Sulphonylureas GliclazideGlipizide MonodiabGlipenclamideGlimepiride Amyryl
Meglitinides naglitinide Starlixrepaglinide Prandin
GlitazonesThiazolidinediones Pioglitazone Actos
DDP4 inhibitors aka gliptins sitagliptin Januvia
vildagliptin Galvuslinagliptin Trajenta
GLP agonists Exenatide Byetta BydureonLiraglutide Victoza
Combinations sitagliptin+metformin Janumetpioglitazone+metformin Competactvildagliptin +metformin Eucras

 

SIGN 116 Management of diabetes QRG

NICE CG87

Drugs used in type 2 diabetes

Glycaemic Index Diabetes.org

NHS Tayside Diabetes Managed Clinical Network

http://youtu.be/Q_IDb_jvhIw
http://youtu.be/Q_IDb_jvhIw
http://youtu.be/g5XKEyx2nw8
http://youtu.be/iQyru-Enve4

Diabetic control

Effects of intensive glycaemic control for patients with type 2 diabetes BMJ Nov 2011

NICE 2009 CG87

Aspiration HbA1 c = 6.5% 7.0%
Audit/QOF HbA1c < 7.5%
this has been revised

http://www.nice.org.uk/cg66

http://www.nice.org.uk/cg87

Cochrane review suggests cautious approach when reducing blood glucose in type 2 diabetes MeRec Rapid Review Sep 2011

 

Proteinuria and microalbuminuria in DM

http://hacking-medschool.com/dm-ckd

youtu.be.com/ikGl7DPXUK0

www.renal.org

Glycaemic control and adverse outcomes in people with diabetes and CKD NeLM Nov 2011

Check annual serum creatinine and  UACR (performed on a random sample of urine)

microalbumiuria/proteinuria positive  if UACR >2.5 in men  or > 3.5 in women

False +ve results may occur after strenuous exercise, UTIs or glomerulonephritis
If microalbuminuria or proteinuria is present  exclude UTI and repeat twice more (within one month where possible) as it may become an irreversible nephropathy within 6 to 12 months.
If microproteinuria is still present refer to one of the inhouse diabetes team, otherwise check their records (or examine their eyes) to check for retinopathy. If retinopathy is not present or if they have microscopic haematuria then look for a nondiabetes cause of renal disease

Once UACR  ratio is > 6 it becomes less accurate indicator of diabetic nephropathy progression.If the ACR is > 6 send an MSU and repeat the test to exclude confounding variables.If confirmed then urinary Protein:Creatinine Index  (PCI) should be requested instead thereafter.

Ensure good glycaemic control (HBa1c target <7.5%)
Measure, assess and manage cardiovascular risk factors aggressively.
Initiate ACE inhibitor therapy for cardiovascular/renal protection.
Glycaemic control and Hba1c – HBA1c should be checked every three to six months.

 

Hypertension in DM

BP Targets in diabetes
Aspiration BP<140/<80 but if CKD present BP <130/80
Audit/QOF BP<145/<85 but if CKD present BP <140/85

BP control reduces retinopathy, nephropathy, stokes, heart failure and MI. BP control is as important as glycaemic control
ACE inhibitors are usually the first line drug see the hypertension guidelines.

Ramipril starting regime derived from the HOPE study regime and BNF guidelines
If U&Es pre treatment reveal a creatinine < 150 micromol/l and a sodium >130 mmol/l then 2.5 mg Ramipril daily (1.25mg if on lower dose concomitant diuretics) for one week with check U&Es and an increase to 5.0 mg Ramipril for a further three weeks. Recheck U&Es and if indicated increase to 10mg Ramipril and repeat U&Es on an annual basis. If eGFR falls > 25% or creatinine rises by > 30% stop or back titrate treatment (GP update)

Cholesterol and diabetes

Cholesterol targets in Diabetes
Aspirational Cholesterol < 4.0mmol/l and LDL <2.0
Audit/QOF Cholesterol <5.0mmol/l and LDL < 2.5

Type 2 diabetics > 40 years should be considered for a statin

However, the value of statins is limited in those with a low absolute risk (Low risk NICE 2008 = not overweight, non smoker, normotensive, no FH or premature CVD disease, no PMH of CVD disease, no macroalbuminuria AND no high risk lipid profile!)
Aged over 40 initiate simvastatin 40 mg, increase to 80 mg if target not met.
Aged under 40 consider simvastatin 40 mg if cardiovascular risk factors.
lf target not achieved: rosuvastatin 10 mg (if 10% drop needed) otherwise consider ezetimibe 10 mg once-daily.
lf cardiovascular risk is high, consider adding fenofibrate to statin therapy if triglycerides > 2.3 mmol/l

UKPDS CVD risk calculator

 

DM guardian drugs

NICE on lipids, CV risk and diabetes NICE CG87

ACE inhibitor: ramipril 10 mg once-daily or lisinopril 20 or 40 mg for most people or
AR2B: (best evidence: losartan 100 mg once-daily, irbesartan 300 mg once-daily).
NB: No statins or ACE-lor ARBs in pregnancy, 15% fetal malformation.
Diabetes & Primary Care Vol 11 No 3 2009

ACE ARB in Diabetes
Irbesarten 150-300mg in type 2 nephropathy
candesarten in early retinopathy?
DAFNE & DESMOND

SIGN on cardiovascular risk in diabetics SIGN 2010, 116

UKPDS Risk Engine

Diabetic review
GeneralEnquiry How have you been?”
1. Energy levels
2. Polydipsia polyuria
3. Recurrent infections skin, genito-urinary, respiratory
Symptoms Symptoms
Complications
Vision
Sensory disturbance, weakness
Sexual functioning
Chest pain, SOB
Monitoring
Home blood sugar measurements
Compliance with treatment
Social history Smoking, alcohol, diet, exerciseHypos – The patient should always be asked to keep a diary of hypoglycaemic attacks, and should always carry a few glucose tablets these are absorbed within minutes and will abort a ‘hypo reaction.’
Occupation Medications (inc OTC herbals and vitamins)
Driving Pertinent Past History and Pregnancy
Depression Screening for depression in Diabetes and CHD
The two screening questions that have to be asked at the annual review.
During the last month, have you often been bothered by feeling down, depressed or hopeless?
During the last month, have you often been bothered by having little interest or pleasure in doing things?”
If the patient answers ‘yes’ to either question then ask:
Is this something with which you would like help?
If yes, complete PHQ9 and refer GP if score is 10 or more
You must enter the Read code short cut /dep to code that this screening has been performed (you can also tick the appropriate box if using Systm1 template)
But please note there is no requirement to undertake screening if the patient is already on treatment for depression. In which case you must enter the exempting Read code = /exdep
Drugs compliance control guardian drugs – Statin BP -ACE inhibitor if microalbuminuria or raised urinary albumin-creatinine ratio
Examine Ht Wt BMI  Waist circumference BP
Eyes Visual acuity and at least annual retinal screening
Feet Peripheral neuropathy reflexes, sensation
Peripheral pulses
Foot care infections, ulceration, footwearThe patient’s feet should be examined for both circulation and sensation, and the patient should be referred to a podiatrist if necessary. The need for daily foot washing (avoid hot water) and general hygiene, including dental hygiene, should be stressed.NICE CG10 Type 2 diabetes – footcare Jan 2004
Ix Urine microalbuminuria, UACR, ketones
FBC, U&Es,  egfr glucose, HbAlc, lipids (LFTS – statin, glitazone)
Discuss Education, driving, Rx, support groups, complianceSmoking – Read code cessation advice & refer to Practice Nurse smoking cessation service.

 

Diabetic eye screening

Retinal screening should be carried our annually by a trained person, refer to ophthalmologist if necessary.

 

Diabetic foot screening

Diabetic Foot Top Tips Addenbrookes

NICE CG10

Managing diabetic foot complications BMJ 2009

 

Charcot foot

http://care.diabetesjournals.org/content/34/9/2123.abstract

 

Metabolic syndrome

Comments are closed.